Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17285491 | PROTEOLYSIS TARGETING CHIMERA (PROTACS) AS DEGRADERS OF SMARCA2 AND /OR SMARCA4 | January 2024 | August 2024 | Allow | 40 | 1 | 0 | No | No |
| 18553330 | PRODUCTION OF UREA AND MELAMINE | September 2023 | March 2025 | Allow | 17 | 2 | 0 | No | No |
| 18225537 | Synthesis of 1,4-Diazaspiro[5.5]Undecan-3-One | July 2023 | August 2024 | Allow | 13 | 1 | 0 | No | No |
| 18356923 | Inhibitors of the MYST Family of Lysine Acetyl Transferases | July 2023 | March 2024 | Allow | 8 | 2 | 1 | No | No |
| 18302554 | BICYCLIC COMPOUNDS | April 2023 | April 2025 | Allow | 24 | 2 | 1 | No | No |
| 18296930 | CDK9 INHIBITORS | April 2023 | December 2024 | Allow | 20 | 2 | 0 | Yes | No |
| 18191112 | PROCESS FOR THE PREPARATION OF TAUTOMERIC FORMS OF SUNSCREENS | March 2023 | July 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18190224 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | March 2023 | September 2024 | Allow | 17 | 2 | 1 | No | No |
| 18122323 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | March 2023 | April 2024 | Allow | 13 | 0 | 1 | No | No |
| 18185200 | Treatment of cutaneous neurofibromas with Mirdametinib | March 2023 | June 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18178765 | METHOD OF PREPARING INDOLIN-2-ONE COMPOUND AND METHOD OF USING INDOLIN-2-ONE | March 2023 | January 2024 | Allow | 10 | 1 | 0 | No | No |
| 18082622 | SOLID FORMS OF PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS | December 2022 | February 2024 | Allow | 14 | 1 | 0 | No | No |
| 17990401 | APE/REF1 INHIBITORS FOR THE TREATMENT OF CANCER | November 2022 | June 2024 | Allow | 30 | 2 | 0 | Yes | No |
| 17987855 | SALTS AND SOLID FORMS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | November 2022 | May 2024 | Abandon | 18 | 0 | 1 | No | No |
| 17970443 | COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K | October 2022 | December 2024 | Abandon | 26 | 2 | 1 | No | No |
| 17965941 | COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE COMPRISING PHOSPHOLIPASE C ACTIVATOR AS AN ACTIVE INGREDIENT | October 2022 | March 2025 | Abandon | 29 | 3 | 1 | No | No |
| 17936813 | TOPICAL PHARMACEUTICAL COMPOSITION IN GEL FORM COMPRISING AT LEAST AMITRIPTYLINE FOR USE IN THE TREATMENT OF CORONAVIRUS-INDUCED NEUROPATHIC PAIN | September 2022 | December 2024 | Abandon | 26 | 2 | 0 | No | No |
| 17822443 | 5-MEMBERED HETEROARYL-CONTAINING AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | August 2022 | November 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17822445 | 6-MEMBERED HETEROARYL-CONTAINING AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | August 2022 | November 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17846126 | ANGIOTENSIN RECEPTOR BLOCKERS FOR TREATMENT OF FIBROTIC DISEASE | June 2022 | May 2025 | Abandon | 35 | 3 | 0 | No | No |
| 17837417 | Method And Kit For Analysis Of Drug Resistance Of Tumor Cells | June 2022 | January 2025 | Allow | 31 | 3 | 0 | No | No |
| 17578130 | COMPOSITIONS AND METHOD OF TREATING CANCER | January 2022 | June 2025 | Allow | 40 | 1 | 1 | No | No |
| 17620238 | NEW EGFR INHIBITORS | December 2021 | June 2025 | Allow | 42 | 1 | 0 | No | No |
| 17612778 | METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING A BRUTON'S TYROSINE KINASE INHIBITOR | November 2021 | May 2025 | Allow | 42 | 1 | 0 | No | No |
| 17606317 | N-((HETEROARYL)METHYL)-1-TOSYL-1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | October 2021 | June 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17606303 | NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | October 2021 | April 2025 | Allow | 42 | 2 | 0 | No | No |
| 17604744 | Abelson Non-Tyrosine Kinase Compounds for the Treatment of Neurodegenerative Diseases | October 2021 | April 2025 | Allow | 42 | 1 | 0 | No | No |
| 17594298 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | October 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17600010 | ANTIMICROBIAL COMPOSITION | September 2021 | May 2025 | Allow | 44 | 1 | 1 | No | No |
| 17598074 | METHOD OF TREATING MALIGNANT RHABDOID TUMOR OF THE OVARY AND SMALL CELL CANCER OF THE OVARY OF THE HYPERCALCEMIC TYPE | September 2021 | April 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17442329 | ESTROGEN RECEPTOR DEGRADING PROTACS | September 2021 | April 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17438801 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | September 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17438341 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | September 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17436448 | LIPIDIC ANALOGS OF ANTI-CANCER STEM CELL AGENT | September 2021 | March 2025 | Allow | 42 | 2 | 0 | Yes | No |
| 17436547 | METHODS FOR THE TREATMENT OF PERIMENOPAUSE AND MENOPAUSE | September 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17433174 | ACYL-COA SYNTHETASE 4 (ACSL4) INHIBITORY COMPOUND | August 2021 | December 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17433226 | METHODS OF SYNTHESIS AND INTERMEDIATES | August 2021 | March 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17428564 | HMG-CoA Reductase Degradation Inducing Compound | August 2021 | July 2025 | Allow | 47 | 2 | 1 | No | No |
| 17310429 | THERAPEUTICALLY ADMINISTRABLE HIGH DOSE NON-AQUEOUS CURCUMINOID SOLUTIONS | August 2021 | September 2024 | Allow | 38 | 2 | 0 | No | No |
| 17427611 | CRYSTALS OF QUINOLONE DERIVATIVES | July 2021 | April 2025 | Allow | 44 | 1 | 1 | No | No |
| 17425426 | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-�R1 KINASE INHIBITOR | July 2021 | April 2025 | Allow | 45 | 2 | 1 | No | No |
| 17422510 | NLRP3 MODULATORS | July 2021 | March 2025 | Allow | 44 | 2 | 1 | No | No |
| 17420391 | CANCER TREATMENT USING MULTI-TARGETED KINASE INHIBITOR IN COMBINATION OF PROTEIN KINASE BIOMARKERS | July 2021 | December 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17418718 | ANTIMICROBIAL COMPOSITIONS WITH 1,2-ALKANEDIOLS | June 2021 | January 2025 | Allow | 42 | 2 | 0 | Yes | No |
| 17352734 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | June 2021 | June 2025 | Allow | 48 | 2 | 1 | No | No |
| 17414286 | AGENT CONTAINING 4-PHENYLBUTYRATE, FOR PREVENTING OR TREATING PRESBYOPIA | June 2021 | January 2025 | Allow | 43 | 2 | 0 | No | No |
| 17288946 | Diphenyl-like Compound, Intermediate Thereof, Preparation Method Therefor, Pharmaceutical Composition Thereof And Uses Thereof | June 2021 | November 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17413413 | 7-PHENOXY-N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)-6,7-DIHYDRO-5H-PYRROLO[1,2-B][1,2,4]TRIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | June 2021 | August 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 15734105 | PHARMACEUTICAL COMPOSITION FOR TREATING KIDNEY CANCER AND APPLICATION THEREOF | June 2021 | August 2024 | Allow | 44 | 1 | 0 | No | No |
| 17311616 | USE OF SODIUM 2-(3-PENTYLPHENYL)ACETATE IN THE TREATMENT OF ALSTR�M SYNDROME | June 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17252677 | USE OF TYROSINE HYDROXYLASE INHIBITORS FOR THE TREATMENT OF AORTIC ANEURYSM | May 2021 | October 2024 | Abandon | 46 | 1 | 0 | No | No |
| 17296150 | INHIBITORS OF ARGINASE | May 2021 | October 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17295848 | PHARMACEUTICAL METHODS | May 2021 | October 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17295092 | PYRROLIDINONE DERIVATIVES AS FORMYL PEPTIDE 2 RECEPTOR AGONISTS | May 2021 | December 2024 | Allow | 43 | 1 | 1 | No | No |
| 17313933 | EPINEPHRINE SPRAY FORMULATIONS | May 2021 | August 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17245388 | TRANS-4-HYDROXYCYCLOHEXYL PHENYL AMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | April 2021 | July 2024 | Allow | 38 | 1 | 0 | No | No |
| 17288707 | PYRIMIDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF | April 2021 | August 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17288328 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | April 2021 | November 2024 | Allow | 42 | 2 | 0 | No | No |
| 17288164 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | April 2021 | September 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17287478 | NOVEL USES | April 2021 | September 2024 | Allow | 41 | 1 | 1 | No | No |
| 17286581 | SOLID DISPERSIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING A SUBSTITUTED INDANE AND METHODS FOR THE PREPARATION AND USE THEREOF | April 2021 | May 2025 | Allow | 49 | 3 | 1 | No | No |
| 17284409 | METHODS FOR MONITORING TUMOR LYSIS SYNDROME | April 2021 | August 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17284200 | COMPOSITIONS FOR THE TREATMENT OF BRAIN TUMORS | April 2021 | March 2025 | Allow | 47 | 2 | 0 | No | No |
| 17282917 | Fused Bicyclic Heterocycles as Therapeutic Agents | April 2021 | April 2025 | Allow | 49 | 3 | 0 | No | No |
| 17282821 | NOVEL ARYLALKYL PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | April 2021 | July 2024 | Allow | 39 | 1 | 0 | No | No |
| 17282789 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | April 2021 | July 2024 | Allow | 39 | 1 | 0 | No | No |
| 17220977 | SYSTEMS AND METHODS FOR TREATING CANCER | April 2021 | November 2024 | Allow | 44 | 2 | 0 | No | No |
| 17281408 | USE OF INHIBITORS OF STRESS GRANULE FORMATION FOR TARGETING THE REGULATION OF IMMUNE RESPONSES | March 2021 | November 2024 | Abandon | 44 | 1 | 1 | No | No |
| 17281453 | COMBINATION THERAPY FOR THE TREATMENT OF UVEAL MELANOMA | March 2021 | May 2024 | Allow | 38 | 1 | 0 | No | No |
| 17281078 | PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS | March 2021 | September 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17280637 | PROCESS OF MANUFACTURE OF A COMPOUND FOR INHIBITING THE ACTIVITY OF SHP2, AS WELL AS PRODUCTS RESULTING FROM ACID ADDITION | March 2021 | July 2024 | Allow | 39 | 2 | 0 | No | No |
| 17278916 | AZD0328 DOSAGE REGIME FOR TREATING COGNITIVE IMPAIRMENT | March 2021 | August 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17196820 | COMBINATION OF ENZASTAURIN AND INHIBITORS OF BTK AND USES THEREOF | March 2021 | June 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17185319 | TETRAHYDRO- PYRIDO[3,4- b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | February 2021 | September 2024 | Allow | 43 | 2 | 0 | Yes | No |
| 17271354 | INHIBITORY MATERIAL AGAINST HUMAN BODY-DERIVED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE-DEPENDENT STEROID DEHYDROGENASE-LIKE, AND ANTICANCER AGENT COMPRISING SAME AS EFFECTIVE INGREDIENT OR PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT FOR TREATMENT OF HYPERLIPIDEMIA | February 2021 | November 2024 | Allow | 45 | 3 | 0 | No | No |
| 17182363 | 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT | February 2021 | July 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17269325 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | February 2021 | August 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 17178916 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | February 2021 | June 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17175252 | Methods and Compositions for Maximizing the Prevention and/or Reduction of Various Maladies and Drug Side-Effects Using Uridine | February 2021 | June 2025 | Allow | 52 | 4 | 1 | No | No |
| 17266863 | Heterocyclic Flavone Derivatives, Compositions, and Methods Related Thereto | February 2021 | February 2024 | Allow | 37 | 1 | 0 | No | No |
| 17168265 | Ceritinib Formulation | February 2021 | March 2025 | Allow | 49 | 2 | 1 | No | No |
| 17263663 | THERAPEUTIC COMPOSITION AND RELATED METHODS | January 2021 | May 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17022294 | FORMULATION INCLUDING DOXYCYCLINE HYCLATE AND METHOD FOR ADMINISTERING THE SAME | September 2020 | April 2024 | Allow | 43 | 2 | 0 | Yes | No |
| 17020168 | N-BROMOTAURINE SOLUTIONS AND EMULSIONS AGAINST ABNORMAL CELLS | September 2020 | April 2024 | Allow | 43 | 2 | 0 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner MARTIN, KEVIN STEPHEN works in Art Unit 1624 and has examined 84 patent applications in our dataset. With an allowance rate of 64.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner MARTIN, KEVIN STEPHEN's allowance rate of 64.3% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MARTIN, KEVIN STEPHEN receive 1.35 office actions before reaching final disposition. This places the examiner in the 27% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by MARTIN, KEVIN STEPHEN is 41 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +42.3% benefit to allowance rate for applications examined by MARTIN, KEVIN STEPHEN. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 77.3% of cases where such amendments are filed. This entry rate is in the 94% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 54.5% are granted (fully or in part). This grant rate is in the 68% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.